Clinical Trials Logo

Clinical Trial Summary

Adenocarcinoma of the anus is rare. It concerns less than 10% of anal cancers and its incidence is less than 0.2/100 000 inhabitants. Its management is not consensual and is most often derived by analogy with that of adenocarcinoma of the lower rectum. This is due to the rarity but also to the diversity of anatomical (anal margin, anal canal, lower rectum), etiological (primary glandular tumors or secondary to anal fistula, primary distant tumor and/or Crohn's disease) and histological forms (mucinous, intestinal, glandular adenocarcinomas and primary or secondary Paget's disease). Most of the literature consists of small case series and simple clinical cases in which the prognosis of these subforms has not been studied.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05605873
Study type Observational
Source Groupe Hospitalier Paris Saint Joseph
Contact
Status Active, not recruiting
Phase
Start date September 16, 2022
Completion date December 31, 2023

See also
  Status Clinical Trial Phase
Terminated NCT02407561 - Prospective Validation Study for the Proprietary Rectal and Anal Cancer Protein Expression Assays N/A